Drug Profile

NV 5138

Alternative Names: NV-5138; SPN 820; SPN-820/821; SPN-821

Latest Information Update: 17 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Navitor Pharmaceuticals; X-Chem
Developer Navitor Pharmaceuticals; Supernus Pharmaceuticals
Class Amines; Antidepressants; Fluorinated hydrocarbons; Pentanoic acids; Small molecules
Mechanism of Action MTORC1 protein stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Depressive disorders; Major depressive disorder

Most Recent Events

17 Sep 2025 Chemical structure information added.
05 Aug 2025 Supernus Pharmaceuticals plans a phase IIb trial for Major depressive disorders (Adjunctive treatment) in 2025
06 May 2025 Supernus Pharmaceuticals plans a phase IIb trial for Major depressive disorder

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com